

# Antiviral Therapies Market Our look at the biggest trends hitting the industry over the coming 12 months

*Surge in problem of viral infection and stronger pipeline of anti-viral drugs across the globe drive the global anti-viral therapies market*

PORTLAND, OR, UNITED STATES, October 15, 2020 /EINPresswire.com/ -- The research report published by Allied Market Report states that the global anti-viral therapies market is estimated to reach \$46.21 billion by 2026. The report provides an in-depth analysis of growth factors, opportunities, market trends, key segments, and competitive landscape. Current market conditions and the future scenario of various regions have been analyzed in the


report to help market players in devising expansion strategies. Moreover, it includes country-wise analysis of each region. Product portfolio and business segments of leading market players outline the competitive scenario. The report provides insights to help investors, stakeholders, and new entrants to determine potential opportunities and tap on them to gain competitive advantage.

“

Increase in number of product approvals for combination therapy is expected to boost the market growth in the coming years”

*Mangesh Panhale*

coming years.



Anti-Viral Therapies

Drivers, restraints, and opportunities

Increase in problem of viral infection and stronger pipeline of anti-viral drugs across the globe drive the growth of the global anti-viral therapies market. However, high cost of anti-viral therapies hinders the market growth. On the other hand, rise in number of product approvals for combination therapy create new opportunities in the

To Get the Sample Copy of Report Visit @ <https://www.alliedmarketresearch.com/request-sample/6643>

#### COVID-19 Scenario:

- The coronavirus outbreak has not much affected the global anti-viral therapies market. In addition, the anti-viral therapies also include essential treatments on HIV, hepatitis and herpes, which drive the demand in the market.
- Moreover, due to the rise in awareness regarding common symptoms of coronavirus, the market has observed increased use of anti-viral therapies, which may aid the industry in terms of revenue

The branded drugs segment to maintain its lead status in terms of revenue throughout the forecast period

Based on type, the branded drugs segment accounted for more than half of the global anti-viral therapies market in 2018, and is expected to maintain its lead status in terms of revenue throughout the forecast period. This is due to availability of large number of branded drugs for treating various viral infections. However, the generic drugs segment is estimated to portray the highest CAGR of 2.5% from 2019 to 2026, owing to increase in number of branded drugs losing their patents

For Purchase Enquiry @ <https://www.alliedmarketresearch.com/request-sample/6643>

The nucleotide polymerase inhibitor segment to maintain its leadership position during the forecast period

Based on mechanism of action, the nucleotide polymerase inhibitor segment contributed to the highest market share with nearly two-fifth of the global anti-viral therapies market in 2018, and is estimated to maintain its leadership position during the forecast period. This is attributed to its increasing usage in Hepatitis C infection and is considered to be the first-line treatment for any viral infection. However, the reverse transcriptase inhibitors segment is estimated to generate the fastest CAGR of 3.1% from 2019 to 2026. This is attributed to increase in FDA approvals for treating viral infection by reverse transcriptase inhibitor mechanism.

North America to maintain its dominant by 2026

Based on region, North America accounted for the highest share based on revenue, holding for more than one-third of the global anti-viral therapies market in 2018, and is projected to maintain its dominant position throughout the forecast period. This is attributed to rise in incidences of infectious diseases across the region. However, Asia-Pacific is estimated to portray the fastest CAGR of 2.8% from 2019 to 2026, owing to growing population base infected with infectious

diseases in the region, presence of several generic pharmaceutical players, and increase in investment for drug development in South Asian countries.

Access Full Report @ <https://www.alliedmarketresearch.com/anti-viral-therapies-market-A06278>

The Major Key Players Are:

- E. Hoffmann-LaRoche Ltd.
- Gilead Sciences
- Glaxo Smith Kline
- Bristol-Myers-Squibb
- Abbott Laboratories
- Astra Zeneca plc
- Abb Vie Inc.
- Aurobindo Pharma Limited
- Johnson & Johnson
- Merck & Co.,Inc.

Similar Reports:

[mHealth Market Analysis and Industry Forecast, 2027](#)

[Cancer Immunotherapy Market Analysis and Industry Forecast, 2027](#)

[Bio-Detection Market Analysis and Industry Forecast, 2027](#)

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa  
Allied Analytics LLP  
+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/528465419>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.